Christine Herdman
Gastroenterology · Newark, DENPI 1487783767
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 414 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 41.3% of the total. 2025 is the largest year on record at $2,024, 2.3 times the $875 reported in 2019.
Across 414 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$870
- Johnson & Johnson$652
- Takeda Pharmaceuticals U.S.A., Inc.$438
- Regeneron Healthcare Solutions, Inc.$325
- Sanofi$273
- plus $2K from 25 others
What the payments were for
- Food & beverage$7,410100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 176 | $3,067 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 48 | $870 |
| Johnson & Johnson | 35 | $652 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $438 |
| Regeneron Healthcare Solutions, Inc. | 18 | $325 |
| Sanofi | 11 | $273 |
| Ardelyx, Inc. | 14 | $270 |
| Pfizer | 11 | $172 |
| Ironwood Pharmaceuticals, Inc | 10 | $161 |
| Gilead | 8 | $156 |
| Madrigal Pharmaceuticals | 9 | $155 |
| QOL Medical, LLC | 7 | $123 |
| Lilly USA, LLC | 5 | $105 |
| Ferring Pharmaceuticals Inc. | 5 | $86 |
| Amgen | 4 | $80 |
| Bristol Myers Squibb | 4 | $77 |
| Novo Nordisk | 2 | $52 |
| Intercept Pharmaceuticals, Inc. | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 4 | $39 |
| Biofire Diagnostics, LLC | 1 | $38 |
| Micro-tech Endoscopy USA, Inc. | 2 | $37 |
| Fresenius Kabi USA, LLC | 2 | $36 |
| Aimmune Therapeutics, Inc. | 2 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Boehringer Ingelheim | 1 | $23 |
| Sandoz | 1 | $17 |
| Evoke Pharma, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Covidien LP | 1 | $16 |
| Shionogi Inc | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$7,423 in reported general payments places this provider in the 75th percentile of 50 gastroenterology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 20 | $36,249 |
| LinzessLinaclotide | 24 | $33,151 |
| XifaxanRifaximin | 13 | $28,038 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 43 | $7,262 |
| Dexlansoprazole DrDexlansoprazole | 12 | $7,173 |
| Famotidine | 114 | $6,989 |
| Omeprazole | 358 | $6,233 |
| Ursodiol | 17 | $5,641 |
| Mesalamine | 11 | $4,282 |
| Lubiprostone | 11 | $2,529 |
| CholestyramineCholestyramine (With Sugar) | 19 | $1,676 |
| Colestipol Hcl | 12 | $1,490 |
| Pantoprazole Sodium | 106 | $1,470 |
| Esomeprazole Magnesium | 20 | $1,100 |
| Dicyclomine Hcl | 43 | $571 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $3,067 | $69,40044 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $870 | $28,03813 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $86 | $7,26243 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 50 gastroenterology providers in Delaware.
Other gastroenterology in Newark
- Michael BrooksNewark$48K
- Jorge UribeNewark$11K
- Laura ConnorNewark$11K
- Gaurav JainNewark$10K
- Jared HossackNewark$9K
- Melissa VitoloNewark$8K
- Scott MeyersonNewark$7K
- Thirumaleshawar KanchanaNewark$7K
- Hasan AliNewark$6K
- Nathan MerrimanNewark$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.